ZA973843B - Treatment of asthma with TNFR-lg. - Google Patents
Treatment of asthma with TNFR-lg.Info
- Publication number
- ZA973843B ZA973843B ZA9703843A ZA973843A ZA973843B ZA 973843 B ZA973843 B ZA 973843B ZA 9703843 A ZA9703843 A ZA 9703843A ZA 973843 A ZA973843 A ZA 973843A ZA 973843 B ZA973843 B ZA 973843B
- Authority
- ZA
- South Africa
- Prior art keywords
- tnfr
- asthma
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1684296P | 1996-05-08 | 1996-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA973843B true ZA973843B (en) | 1997-11-10 |
Family
ID=21779275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9703843A ZA973843B (en) | 1996-05-08 | 1997-05-05 | Treatment of asthma with TNFR-lg. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0910413A2 (en) |
| JP (1) | JP2000510113A (en) |
| KR (1) | KR20000010825A (en) |
| CN (1) | CN1233189A (en) |
| AR (1) | AR007020A1 (en) |
| AU (1) | AU725408B2 (en) |
| BR (1) | BR9708928A (en) |
| CA (1) | CA2253557A1 (en) |
| CO (1) | CO4820397A1 (en) |
| HR (1) | HRP970224A2 (en) |
| MA (1) | MA24169A1 (en) |
| PE (1) | PE70698A1 (en) |
| TR (1) | TR199802238T2 (en) |
| WO (1) | WO1997041895A2 (en) |
| ZA (1) | ZA973843B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002508934A (en) * | 1997-12-29 | 2002-03-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Novel nucleic acids and polypeptides having homology to the TNF receptor |
| TR200504220T2 (en) * | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins. |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| DE602004013557D1 (en) * | 2003-02-28 | 2008-06-19 | Ares Trading Sa | LIQUID FORMULATIONS OF THE TUMORNEKROSE FRACTURE BINDING PROTEIN TBP-1 |
| TWI374935B (en) * | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| EP2311481A3 (en) | 2006-10-20 | 2013-10-16 | Biogen Idec MA Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1132471A3 (en) * | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-binding proteins |
| AU670125B2 (en) * | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| US5684222A (en) * | 1993-01-22 | 1997-11-04 | Ontario Cancer Institute | Mutant mouse having a disrupted TNFRp55 |
| CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| BR9508419A (en) * | 1994-07-22 | 1997-11-18 | Hoffmann La Roche | Pharmaceutical compositions comprising a cholinergic tnf binding protein |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
-
1997
- 1997-05-02 JP JP09539522A patent/JP2000510113A/en active Pending
- 1997-05-02 TR TR1998/02238T patent/TR199802238T2/en unknown
- 1997-05-02 EP EP97921849A patent/EP0910413A2/en not_active Withdrawn
- 1997-05-02 WO PCT/EP1997/002256 patent/WO1997041895A2/en not_active Application Discontinuation
- 1997-05-02 CA CA002253557A patent/CA2253557A1/en not_active Abandoned
- 1997-05-02 BR BR9708928-1A patent/BR9708928A/en not_active Application Discontinuation
- 1997-05-02 MA MA24590A patent/MA24169A1/en unknown
- 1997-05-02 AU AU27764/97A patent/AU725408B2/en not_active Ceased
- 1997-05-02 KR KR1019980708961A patent/KR20000010825A/en not_active Application Discontinuation
- 1997-05-02 HR HR60/016,842A patent/HRP970224A2/en not_active Application Discontinuation
- 1997-05-02 CN CN97194455A patent/CN1233189A/en active Pending
- 1997-05-05 ZA ZA9703843A patent/ZA973843B/en unknown
- 1997-05-05 PE PE1997000351A patent/PE70698A1/en not_active Application Discontinuation
- 1997-05-06 AR ARP970101876A patent/AR007020A1/en not_active Application Discontinuation
- 1997-05-07 CO CO97024335A patent/CO4820397A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU725408B2 (en) | 2000-10-12 |
| MA24169A1 (en) | 1997-12-31 |
| KR20000010825A (en) | 2000-02-25 |
| WO1997041895A2 (en) | 1997-11-13 |
| HRP970224A2 (en) | 1998-04-30 |
| AU2776497A (en) | 1997-11-26 |
| WO1997041895A3 (en) | 1998-03-12 |
| CA2253557A1 (en) | 1997-11-13 |
| CN1233189A (en) | 1999-10-27 |
| JP2000510113A (en) | 2000-08-08 |
| PE70698A1 (en) | 1998-11-18 |
| BR9708928A (en) | 2000-05-09 |
| CO4820397A1 (en) | 1999-07-28 |
| TR199802238T2 (en) | 1999-02-22 |
| EP0910413A2 (en) | 1999-04-28 |
| AR007020A1 (en) | 1999-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9411080D0 (en) | Treatment | |
| ZA979731B (en) | Treatment of asthma. | |
| ZA97986B (en) | Treatment of liquors. | |
| ZA978359B (en) | Novel treatment | |
| ZA978640B (en) | Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis. | |
| GB9410512D0 (en) | Novel treatment | |
| ZA973843B (en) | Treatment of asthma with TNFR-lg. | |
| ZA976350B (en) | Treatment of liquid. | |
| ZA976593B (en) | Novel treatment | |
| GB9411635D0 (en) | Novel treatment | |
| ZA977867B (en) | Method of treatment. | |
| GR3032700T3 (en) | Air treatment | |
| GB9608657D0 (en) | Novel treatment | |
| ZA973380B (en) | Treatment of washwater. | |
| GB9726223D0 (en) | The treatment of materials | |
| ZA951226B (en) | The treatment of gaseous substances | |
| GB9625795D0 (en) | Novel treatment | |
| GB9612752D0 (en) | Novel treatment | |
| ZA9711116B (en) | The treatment of materials. | |
| HU9600619D0 (en) | Treatment with onion-oil | |
| GB9617762D0 (en) | Treatment | |
| AUPO019296A0 (en) | Treatment of asthma | |
| GB9614740D0 (en) | Novel treatment | |
| GB9616410D0 (en) | Novel treatment | |
| GB9616409D0 (en) | Novel treatment |